Welcome to our dedicated page for Bausch Health Companies news (Ticker: BHC), a resource for investors and traders seeking the latest updates and insights on Bausch Health Companies stock.
Bausch Health Companies Inc. (NYSE: BHC, TSX: BHC) generates a wide range of news relevant to investors, health care professionals and industry observers. As a global, diversified pharmaceutical company with operations in gastroenterology, hepatology, neurology, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, its disclosures cover both business performance and strategic activity.
News updates commonly include financial results and segment performance, such as quarterly revenue trends across Salix, International, Solta Medical, Diversified Products and Bausch + Lomb. The company also releases information on capital structure actions, including exchange offers for senior secured notes and amendments to credit agreements at Bausch Health and Bausch + Lomb, which are detailed in press releases and Form 8-K filings.
Bausch Health’s news flow highlights business development and acquisitions, for example the acquisition of DURECT Corporation to expand its hepatology portfolio and the acquisition of Wuhan Shibo Zhenmei Technology Co., Ltd. to strengthen Solta Medical’s distribution in China. Product and geographic expansion updates, such as OraPharma’s commercial expansion into Canada and Puerto Rico and regulatory milestones for aesthetic devices, also feature prominently.
In addition, the company announces conference participation and investor events, including presentations at healthcare conferences where management provides strategic and business updates and may discuss guidance ranges. For those tracking BHC, this news page offers a centralized view of official announcements on operations, financing, governance and growth initiatives. Investors and followers of the pharmaceutical and medical aesthetics sectors can review these items to understand how Bausch Health is executing on its stated priorities and managing its diversified portfolio.
Summary not available.
Bausch Health Companies Inc. (NYSE/TSX: BHC) announced the publication of a post-hoc analysis in The Journal of Emergency Medicine supporting RELISTOR (methylnaltrexone bromide) injection for treating opioid-induced constipation in severely ill patients with insufficient laxative response. The study revealed a significant increase in rescue-free laxation rates: 61.4% within 4 hours compared to 16% for placebo. Notably, RELISTOR did not compromise opioid pain relief, although gastrointestinal side effects were reported. This reinforces RELISTOR's therapeutic value, particularly in emergency settings.
Bausch Health Companies Inc. (NYSE/TSX: BHC) announced that its dermatology product, JUBLIA® (efinaconazole) Topical Solution, has received the American Podiatric Medical Association (APMA) Seal of Approval. This recognition signifies the product's safety and efficacy in treating onychomycosis, a common fungal infection affecting toenails. JUBLIA® has been available since 2014 for adults and was approved for children in 2020. The APMA's endorsement comes after a rigorous scientific review process, enhancing JUBLIA's credibility in the market.
Bausch Health and Salix Pharmaceuticals launched digital initiatives for Constipation Awareness Month, focusing on opioid-induced constipation (OIC), irritable bowel syndrome with constipation (IBS-C), and chronic idiopathic constipation (CIC). Their campaign aims to enhance patient education and awareness through platforms like TikTok and revamped websites, including UnderstandingOIC.com. Highlights include partnerships with healthcare influencers to discuss symptoms and treatment options, addressing the fact that 40-80% of chronic pain patients experience OIC.
Bausch + Lomb, part of Bausch Health (NYSE/TSX: BHC), announced that its exclusive recycling programs, ONE by ONE and Biotrue®, have successfully recycled over 41 million units (248,516 pounds) of used contact lens and eye care materials. The Biotrue® program is the first of its kind in the U.S., having collected more than 65,000 units since launch. These initiatives, in partnership with TerraCycle, promote sustainability by addressing waste that typically ends up in landfills. The company aims to expand these efforts to further reduce environmental impact.
Kroll Bond Rating Agency (KBRA) has released its Third-Quarter 2021 U.S. Bank Compendium, providing insights into the U.S. banking sector's performance and outlook for 2022. The report reviews 3Q21 results for U.S. banks under KBRA ratings, focusing on key credit metrics and ratios. Additionally, it highlights the top 10 banks with the lowest cost deposits and analyzes changes in return on assets and nonperforming asset ratios. The compendium also includes a detailed supplement of 187 rated bank debt issues. Amalgamated Financial Corp. (NASDAQ: AMAL) holds a BBB rating with a Stable Outlook.
Bausch Health Companies Inc. (NYSE/TSX: BHC) announced that its gastroenterology business, Salix Pharmaceuticals, will present new data on rifaximin at The Liver Meeting™ 2021, taking place virtually from Nov. 12-15, 2021. Two abstracts will be available to registered attendees, highlighting studies on rifaximin's role in reducing hospitalization and mortality in patients with hepatic encephalopathy, as well as its use in emergency department services for cirrhosis patients. XIFAXAN® (rifaximin) is indicated for reducing hepatic encephalopathy recurrence and treating IBS-D.
Bausch Health Companies (NYSE/TSX: BHC) announced its participation in two significant investor conferences. The leadership team, including Joseph C. Papa and Sam Eldessouky, will present at the Credit Suisse 30th Annual Healthcare Conference on Nov. 10, 2021, at 10:30 a.m. ET, and at the Evercore ISI HealthCONx Conference on Dec. 1, 2021, at 1:00 p.m. ET. A live webcast will be available on the company’s Investor Relations page.
Bausch Health Companies reported third-quarter 2021 revenues of $2.111 billion, down 1% from $2.138 billion year-over-year. GAAP net income surged to $188 million, compared to $71 million in Q3 2020. The company plans to launch IPOs for Solta Medical in December 2021 or January 2022, followed by Bausch + Lomb about 30 days later. Bausch Health reaffirmed its full-year 2021 guidance with revenue expectations of $8.40 – $8.60 billion and Adjusted EBITDA between $3.35 – $3.50 billion.
Bausch Health Companies (NYSE/TSX: BHC) will present seven scientific posters and data from its ARMOR surveillance study at the American Academy of Optometry and American Academy of Ophthalmology meetings held in November 2021. Key presentations include analyses on the newly FDA-approved XIPERE™ for macular edema and the Bausch + Lomb INFUSE® Multifocal contact lenses. The company's commitment to educating eye care professionals through promotional events highlights its dedication to addressing patient needs.